Acadia Pharmaceuticals Inc. · NASDAQ:ACAD
Acadia Pharmaceuticals — Q3 2024 Earnings Presentation
22 slides from Acadia Pharmaceuticals's earnings presentation, Nov 6, 2024
Slide 1: Third Quarter 2024 Earnings Call
Third Quarter 2024 Earnings Call November 6, 2024
Slide 2: Call Agenda
Call Agenda Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications CEO Opening Remarks Catherine Owen Adams | Chief Executive Officer Commercial Update Brendan Teehan | Chief Operating Officer, Head of Commercial R&D Update Elizabeth H.Z. Thompson | Executive Vic
Slide 3: Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would
Slide 4: Opening Remarks
Opening Remarks Catherine Owen Adams Chief Executive Officer 4
Slide 5: Acadia Overview
Acadia Overview Commercial R&D Financial Two growing commercial Two late -stage assets with 18% YoY revenue growth franchises in DAYBUE and strong early-stage pipeline in 3Q24 NUPLAZID Ongoing P3 trial of ACP-101 in Cash balance of $565.3M Reported $250.4 million Prader-Willi syndrome as of Septembe
Slide 6: Commercial Product Highlights
Commercial Product Highlights DAYBUE NUPLAZID • 3Q net product sales of $91.2M; • 3Q net product sales of $159.2 million; 36% YoY growth and 8% sequential growth 10% YoY growth • Strong launch to-date with many dynamics in • Underlying trends driving growth continue to be common with other rare dise
Slide 7: Deep CNS and Rare Disease Pipeline
Deep CNS and Rare Disease Pipeline Program Indication Preclinical Phase 1 Phase 2 Phase 3 Marketed Hyperphagia in ACP-1011,2 Prader-Willi Syndrome Alzheimer’s Disease ACP-2042 Psychosis Rett Syndrome; Fragile X ACP-25912 Syndrome SYNGAP1; Rett syndrome; ASO Programs2 Undisclosed Multiple Neuropsychi
Slide 8: Commercial Update
Commercial Update Brendan Teehan Chief Operating Officer Head of Commercial 8
Slide 9: DAYBUE Update
DAYBUE Update Number of Patients Receiving Paid Shipments in the Quarter Key 3Q Trends • Continued penetration of the prevalent population • Increasing dispense rates • Discontinuation rates steadied; flattening persistency curve at 12 months+ Persistency Based on Shipments 60% Persistency rates of
Slide 10: DAYBUE Initiatives to Drive Penetration
DAYBUE Initiatives to Drive Penetration Focus on Real-World Experience Translating clinical endpoints to tangible real-world benefits, including stories from HCPs and Caregivers of patients' improved: Purposeful Verbal & Non-Verbal Quality of Life Alertness Mood Engagement Use of Hands Communication
Slide 11: NUPLAZID 3Q Drivers
NUPLAZID 3Q Drivers Real-World Evidence1-3 Findings: • Decreased mortality at 1 year when treating PDP with pimavanserin as compared to off-label atypical antipsychotics • Lower all-cause hospitalizations, ER visits, and shorter length of stays vs. atypical antipsychotics in Net Product Sales Label
Slide 12: NUPLAZID Growth Opportunity
NUPLAZID Growth Opportunity Launched More to Parkinson's disease awareness campaign Early metrics signal one of the most successful campaigns of its kind Concurrently launched a branded campaign featuring NUPLAZID as the only FDA-approved treatment for PDP Majority of benefit from these campaigns ex
Slide 13: R&D Update
R&D Update Elizabeth H.Z. Thompson Executive Vice President Head of Research and Development 13
Slide 14: DAYBUE ROW Regulatory Update
DAYBUE ROW Regulatory Update Canada European Union Japan Health Canada marketing Planned Marketing PMDA discussions authorization granted for Authorization Application ongoing regarding the treatment of Rett (MAA) submission to the study design syndrome in adult and European Medicines Agency pediatr
Slide 15: Continuing to Expand Understanding of NUPLAZID
Continuing to Expand Understanding of NUPLAZID • Integrated analysis of 135 patients with PDP; • Multiple pimavanserin studies have included 21 reported no symptoms after receiving measures related to sleep and sedation pimavanserin • Data suggest pimavanserin may be associated • Earlier treatment a
Slide 16: ACP-101 in Prader-Willi Syndrome
ACP-101 in Prader-Willi Syndrome ACP-101 is intranasally administered carbetocin, an oxytocin analogue designed for improved specificity and half-life Rare and complex neurobehavioral genetic disorder that often Significant leads to social isolation Unmet Need Hyperphagia is a defining characteristi
Slide 17: ACP-204 in Alzheimer's Disease Psychosis (ADP)
ACP-204 in Alzheimer's Disease Psychosis (ADP) ACP-204 is a next generation 5HT2A blocker that builds on the learnings of pimavanserin Target Product Profile Phase 1 Results Mitigate or eliminate QT prolongation No sign of QT prolongation Explore doses higher than pimavanserin Wide dose range establ
Slide 18: Financial Update
Financial Update Mark Schneyer Chief Financial Officer 18
Slide 19: 3Q24 Financial Highlights
3Q24 Financial Highlights Millions, Except EPS 3Q24 3Q23 YoY Change TOTAL Net Sales $250.4 $211.7 18% NN NUPLAZID Net Product Sales $159.2 $144.8 10% DAYBUE Net Product Sales $91.2 $66.9 36% R&D $66.6 $157.0* - SG&A $133.3 $97.9 36% Net Income (Loss) $32.8 ($65.2) - EPS $0.20 ($0.40) - Year End 2023
Slide 20: Updating FY 2024 Financial Guidance
Updating FY 2024 Financial Guidance Prior FY24 Guidance Updated FY24 Guidance NUPLAZID Net Sales $590 - $610 Million $600 - $610 Million NUPLAZID Gross-to-Net 26% - 28% 26% - 27% DAYBUE Net Sales $340 - $370 Million $340 - $350 Million Total Revenue $930 - $980 Million $940 - $960 Million R&D Expens
Slide 21: Building on Our Success in 2024 & Beyond
Building on Our Success in 2024 & Beyond Commercial R&D Financial Two growing commercial Two late -stage assets: Substantial and growing franchises in DAYBUE and ACP-101 in PWS cash flow from operations NUPLAZID ACP-204 in ADP Invest in R&D, pipeline and Build on data generation business development
Slide 22: Q&A Session
Q&A Session 22
ACADIA Pharmaceuticals — Q3 2024 Earnings Presentation on 6ix